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ABSTRACT
This article presents a historical perspective on the different methods
used to measure folate status in populations and clinical settings. I
discuss some of the advantages and limitations of these procedures.
For .50 y researchers have used microbiological assay methods to
assess folate status in clinical settings and in population-based
studies, such as NHANES. Serum and red blood cell folate values
obtained with the Lactobacillus casei assay have formed the basis
for current ranges and cutoffs for the establishment of folate suffi-
ciency and for the current dietary reference intakes for folate. Over
the past 30 y competitive folate protein binding assays, which
are available in kit form, have supplanted microbiological assays
in many clinical laboratories because of their ease of use. Several
NHANES cycles have used these assays. Folate concentrations ob-
tained with these kits are lower than those from microbiological
assays and show a wide variation between different protein binding
assay kits. This variation has complicated the setting of values for
normal ranges of folate status and the comparison of status changes
between different NHANES cycles. The recent development of
mass spectrometry methods for folate opens up the possibility of
measurement of individual folate vitamers such as folic acid. Past
experience with microbiological and competitive protein binding
assays indicates some of the technical problems that research will
need to address before this promise becomes reality. Am J Clin
Nutr doi: 10.3945/ajcn.111.013367.
INTRODUCTION
Folate is the group name for a class of bioactive vitamin
compounds that are based on the folic acid structure and that
are interconverted during metabolism (1–3). A large number of
potential folate derivatives exist that differ in oxidation state, one-
carbon substitution, and polyglutamate chain length (Figure 1).
Folic acid itself does not occur naturally and is usually present
only in individuals who take vitamin supplements or eat fortified
foods. Reduced folates are usually less stable than folic acid and
their stability varies, depending on the one-carbon substitution.
The oxidation of reduced folates usually results in products that
lack vitamin activity, although a small proportion may be con-
verted to biologically active oxidized forms.
The large number of folate derivatives, and the instability of
some of them, as well as the potential for some of them to in-
terconvert chemically after extraction from biological samples,
greatly complicates the identification and assaying of individual
folate vitamers. Historically, most of the assay methods that have
been used to measure folate status have measured total folate,
primarily in serum, plasma, or red blood cells. Microbiological
assay methods, which were originally developed in the 1930s,
were the first method used to measure folate status and were the
“gold standard” for many years. Many laboratories still use these
methods. Over the past 30 y, assays based on competitive protein
binding have become more popular, particularly in clinical lab-
oratories, because of their ease of use and availability in com-
mercial kit form. More recently, a number of laboratories have
introduced mass spectrometry methods that have the potential to
measure individual folate one-carbon forms.
Plasma contains only folate monoglutamates, almost entirely
the 5-methyltetrahydrofolate (5-methyl-THF) form, whereas long-
chain polyglutamates of 5-methyl-THF predominate in red blood
cells. In recent years, interest has increased in the assay of in-
dividual folate one-carbon forms. This increased interest is partly
because of the observation that common genetic polymorphisms,
such as the 677C/T variant in the methylenetetrahydrofolate re-
ductase gene (5), may cause a redistribution of folate one-carbon
forms in red blood cells and possibly other tissues (6). In ad-
dition, the introduction of folic acid fortification of the food
supply, as well as folic acid supplement use, has resulted in the
appearance of free folic acid in blood samples, and some con-
cerns have been raised that the presence of this unnatural form
of folate may have detrimental effects (7).
MICROBIOLOGICAL ASSAY METHODS
The introduction in the 1930s of microbiological assay methods
that used lactic acid bacteria for the detection and assaying of
vitamin factors greatly aided in the discovery, isolation, and
characterization of many B vitamins. These microbiological assay
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methods represented a marked improvement over other bioassay
methods, such as chick growth bioassays, that laboratories used at
that time (8). Most bacteria synthesize folate de novo (as dihy-
drofolate) and cannot transport folate. Bacteria use folate to
synthesize thymidylate, purines, methionine, serine, glycine, and
pantothenate. Bacteria also use folate for f-mettRNA synthesis,
which is necessary for protein synthesis initiation. Lactic acid
bacteria are usually present in the gut and have lost the ability to
synthesize many of the B vitamins and survive in their environ-
ment because they have developed transport systems for various B
vitamins (9, 10).
Folate was originally isolated in the 1940s from spinach, liver
extracts, and Corynebacterium species cultures as a factor that sup-
ported Lactobacillus casei (renamed Lactobacillus rhamnosus,
ATCC 7469) growth (11, 12). A major advantage of assays with L.
casei is that L. casei responds equally well to all folate mono-
glutamate forms (Table 1) (8). Although the affinity for the folate
transporter varies with different monoglutamates, growth promotion
is essentially identical because intracellular one-carbon metabolism,
rather than transport, limits growth on monoglutamates (13, 14).
The authors of one study (15) reported that 5-methyl-THF
produced a significantly decreased growth response compared with
folic acid when the medium’s pH was 6.8, whereas responses were
identical at a pH of 6.2. The pH of 6.2 is the one that researchers
have traditionally used for assays with this microorganism.
L. casei possesses a vitamin B-12–independent polyglutamate-
specific methionine synthase. As a result, the initial metabolism
of transported 5-methyl-THF involves its oxidation to 5,10-
methylene-THF via a NAD-dependent methylenetetrahydrofolate
reductase (13). Growth of L. casei on folate diglutamates is es-
sentially identical to that on monoglutamates. Growth of L. casei
on triglutamates is similar but may be slightly lower.
L. casei is unusual in that it can also transport long-chain
folylpolyglutamates, although the affinity for the transporter
decreases with elongation of the glutamate chain (16, 17). Long-
chain folylpolyglutamates are transported intact and used di-
rectly in one-carbon metabolism, but with these compounds
transport becomes limiting for growth. As a result, the growth
curves obtained in response to folate concentration with poly-
glutamates of chain length .3 are steeper (less exponential)
than those obtained with folylmono- to triglutamates (16). This
phenomenon, called positive drift, prevents the normalization of
growth curves obtained with long-chain polyglutamates to the
curves from shorter derivatives.
Folylpolyglutamates in biological samples such as red blood
cells require hydrolysis to the triglutamate or shorter glutamate
chain length for an accurate assay of total folate by L. casei. Be-
cause folate concentrations in plasma (entirely monoglutamate)
are much lower than those in red blood cells, hydrolysis has
normally been achieved by the lysing of whole blood and in-
cubation of the lysate for 1–2 h, which allows hydrolysis of fo-
lylpolyglutamates by a neutral pH plasma c-glutamyl hydrolase.
In some studies, investigators treated red blood cell extracts
with hog kidney conjugase, which converts folates to mono-
glutamates under acidic conditions, or with chick pancreas
conjugase, which converts folates to the diglutamate form.
Hydrolysis of folylpolyglutamates by these enzymes proceeds
rapidly with the long-chain derivatives but slows down with
shorter polyglutamates, such that the terminal hydrolysis
(usually, the conversion of diglutamate to monoglutamate) is
relatively slow and can be incomplete. Because L. casei responds
well to di- and triglutamates, incomplete hydrolysis of folylpo-
lyglutamates to the monoglutamate is not normally a concern.
FIGURE 1. Structure of folic acid and reduced folylpolyglutamates. Reproduced with permission from reference 4.
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The authors of many studies in the literature, particularly in the
food science area, have used the terms “free” and “total” folate to
denote the folate concentrations that result from assays with
L. casei before and after c-glutamyl hydrolase treatment. These
authors assumed that “free” folate refers to folate monoglu-
tamates and short-chain polyglutamates. However, this greatly ex-
aggerates the amount of short-chain derivatives due to L. casei’s
ability to respond to longer-chain folylpolyglutamates.
L. casei exhibits a growth response not only to folate but also
to products of one-carbon metabolism, and grows in the com-
plete absence of folate if the medium contains thymidine, pu-
rines, methionine, serine, glycine, and pantothenate (14). Human
plasma contains significant concentrations of all of these com-
pounds, with the exception of thymidine. For this reason,
L. casei media for the folate assay contain amino acids, purines,
and pantothenate. Under these conditions, the growth of L. casei
in response to folate is due to the organism’s folate requirement
for thymidylate synthesis.
DIFFERENTIAL MICROBIOLOGICAL ASSAY
The types of folate that support growth of other bacteria can
differ from that observed with L. casei, and these differences in
folate requirement specificity have been used to assess the
amounts of different folate one-carbon forms in biological ex-
tracts (9). L. casei responds to all one-carbon forms of folate
as well as to folic acid, dihydrofolate, and THF. Streptococcus
faecium (formerly known as Streptococcus faecalis or Strepto-
coccus lactis R) also requires folate for growth and responds to
most folate mono- and diglutamates (Table 1). It differs from
L. casei in its inability to grow on tri- or longer polyglutamates
and its inability to use 5-methyl-THF for growth. 5-Methyl-THF
is transported by S. faecium but it cannot metabolize it.
Researchers have used the growth response of S. faecium to
measure the amount of non-methyl-folate in biological extracts
and the amount of 5-methyl-THF, which they calculated by
subtracting the S. fecium value from the value they obtained for
total folate with the use of the L. casei assay (reviewed in ref-
erence 9). S. faecium also differs from L. casei in that it responds
to pteroate derivatives because it possesses dihydrofolate syn-
thetase activity, which L. casei lacks. Pteroates have no folate
activity in humans, who also lack dihydrofolate synthase ac-
tivity. It is not known whether any pteroates are present in hu-
man biological samples, such as plasma.
The folate requirement of Pediococcus cerevisiae (formerly
known as Leuconostoc citrovorum) has been less well charac-
terized (Table 1) (9). This organism is similar to S. faecium in
that it responds to all reduced folate monoglutamates with the
exception of 5-methyl-THF. P. cerevisiae differs from S. faecium
in that folic acid and dihydrofolate, and also 10-formyl folic
acid, which can arise through oxidation of reduced folates, do not
support its growth. Consequently, a reduced folate, normally
5-formyl-THF, rather than folic acid has to be used to generate the
standard curve when this organism is used for microbiological
assay procedures. Differences in folate concentrations obtained
after assay with S. faecium and P. cerevisiae have been used to
calculate the folic acid content of biological samples. However,
this “folic acid” content could also reflect the presence of dihy-
drofolate and/or 10-formyl folic acid in the sample.
An additional drawback in the use of these organisms for
differential microbiological assays of blood samples for routine
folate status assessment relates primarily to the accuracy and
precision of the assays. Assays with S. faecium can provide an
assessment of total non-methyl forms of folate in plasma or red
blood cells but not individual folate one-carbon forms. Mea-
surement of total folate still requires assays with L. casei
because most of the folate in these samples is in the form of
5-methyl-THF.
Comparison of growth responses between S. faecium and P.
cerevisiae may supply information on free folic acid content.
However, because the concentrations of folic acid and non-
methyl folate are typically very low, a comparison of growth
responses would require very high precision and accuracy to
obtain an accurate measure of folic acid by difference. In any
event, the presence of other oxidized derivatives could confound
the results. Although the microbiological methods are very sen-
sitive, it is not clear that they possess sufficient accuracy and pre-
cision for routine assessment of minor folate species. The routine
use of 3 different microorganisms is also quite cumbersome.
The L. casei microbiological assay method for total folate has
proved its efficacy over many years. Plasma and serum samples
can be assayed directly. Red blood cell (or whole-blood) sam-
ples require little manipulation. Although the short hydrolysis
step that the process requires for red blood cell folate can result
in some interconversion of one-carbon forms, all forms promote
similar growth. The assay is relatively inexpensive and does not
require sophisticated instrumentation. The composition of the
medium is well defined, and researchers can prepare the medium
TABLE 1
Relative response of microorganisms to unhydrolyzed folate derivatives1
Lactobacillus
casei
Streptococcus
faecium
Pediococcus
cerevisiae
Folic acid (PteGlu) 96 100 0
10-Formyl-PteGlu 100 100 0
Dihydrofolate 100 100 0
THF 100 100 100
10-Formyl-THF 99 100 100
5-Formyl-THF 100 100 100
5-Methyl-THF 100 0 0
PteGlu2 100 100 0
PteGlu3 100 0 0
PteGlu4 66 — —
PteGlu5 20 — —
PteGlu6 4 — —
PteGlu7 2 — —
10-Formyl-H4PteGlu3 82 — —
10-Formyl-H4PteGlu5 3 — —
5-Methyl-H4PteGlu3 90 0 0
5-Methyl-H4PteGlu5 2 0 0
5-Methyl-H4PteGlu7 1 — —
Pteroate 0 100 0
10-Formyl-pteroate 0 100 0
5-Formyl-H4 pteroate 0 + 0
1 In most cases, the relative response is a comparison of folate concen-
tration required to support half maximum growth rates of the bacterium. The
data were adapted from reference 9. All reduced folates refer to the natural
isomer at the C-6 position. 6R,S-5-Methyl-THF and 6R,S-5-formyl-THF,
which researchers sometimes use as standards, exhibit half the activity of
the 6S-derivatives that correspond to them. THF, tetrahydrofolate; +, some
growth but not quantitated.
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in a laboratory or obtain it from commercial sources. Bacterial
growth is normally monitored by light transmission (actually
light scattering) but can also be measured with the use of a pH
meter because lactic acid bacteria produce lactate, and the me-
dium’s pH decreases from 6.1 to 4.7 at full growth. Because this
organism produces energy by anaerobic metabolism, a shaking
incubator is not required.
The L. casei assay procedure was further simplified ’20 y
ago with the introduction of a 96-well microplate technique (18–
20). The assay’s major experimental drawback is the need to
maintain aseptic conditions because the growth medium is very
rich. In some instances, particularly in clinical settings, the
presence of antibiotics in blood samples may interfere with the
assay. Antibiotic (chloramphenicol)-resistant strains of L. casei
were introduced a number of years ago to allow the use of this
bacterium for routine clinical laboratories (20).
ASSESSMENT OF FOLATE STATUS
Approximately 50 y ago Baker et al (21) developed L. casei
assay methods for the measurement of folate status and clinical
folate insufficiency. The blood folate values that this assay pro-
duced at that time still form the basis for our current assessment
of folate status adequacy and were the basis for the current folate
dietary reference intake.
In a classic study by Herbert (22), who fed an adult male subject
a folate-depleted (and inadvertently potassium-depleted) diet,
serum folate concentrations fell before any other indicator of
deficiency. Serum folate concentrations fell after 3 wk on the diet;
sustained neutrophil hypersegmentation occurred after 11 wk; red
blood cell folate concentrations declined after 17 wk; and Herbert
observed megaloblastic marrow, a red cell count drop, and a sus-
tained increase in urinary formiminoglutamate (see below) after
19 wk. This and many other clinical and nutritional studies at
around the same time (reviewed in 23) led to the concept that
serum (or plasma) folate is an indicator of recent folate intake,
and fasting concentrations are a better indicator of short-term
status (23). Red blood cell folate reflects tissue stores because red
blood cells only accumulate folate during erythropoiesis. Fur-
thermore, red blood cell folate concentrations change slowly with
changes in intake because of the red blood cell’s 120-d life span.
These early studies suggested that a serum folate concentration
,3 ng/mL represented clinical deficiency, concentrations between
3 and 6 ng/mL were marginal, and 6–20 ng/mL was the normal
range. These ranges were the basis for the World Health Organ-
ization’s serum folate guidelines in 1972 (24). The lack of meg-
aloblastic changes in subjects with red blood cell folate
concentrations .140 ng/mL also formed the basis for the defini-
tion of the estimated average requirement for folate in the current
National Academy of Sciences dietary reference intakes (25).
COMPETITIVE PROTEIN BINDING ASSAYS
Clinical laboratories and population studies have used com-
petitive binding assays widely for folate status assays since the
1970s. In many cases, competitive binding assays have sup-
planted the use of microbiological assays, primarily because of
their ease of use and availability in commercial kit form. The
initial competitive protein binding assays were based on serum or
milk folate binders (26–29). Milk contains a soluble form of the
high-affinity folate binding protein (folate receptor). Unlike the
microbiological assay methods, which measure the metabolic use
of folate and consequently growth, the binding assays measure
the competition between a labeled folate standard and unlabeled
folate from biological extracts for a folate binder. The ability of
folate in the biological sample to compete with the labeled folate
standard depends on its relative affinities for the binding protein.
Folic acid has higher affinity than 5-methyl-THF for folate
binding proteins, and the affinity of formyl-THF derivatives is
somewhat lower. An early comparison of multiple commercial
kits (30) showed differences in the response to different folate
monoglutamate standards and folylpolyglutamate standards. With
some kits, folylpolyglutamates bound with significantly higher
affinity than monoglutamates and thus appeared to contain falsely
high folate concentrations.
Accurate red blood cell folate measurements require complete
conversion of red cell folate to the monoglutamate derivative. The
different affinities of various monoglutamates for the binder are
not a problem if 5-methyl-THF is the predominant one-carbon
form in serum and red blood cells. However, the different af-
finities of various monoglutamates for the binder is a problem if
significant concentrations of other one-carbon forms are present,
such as in the red blood cells of methylenetetrahydrofolate re-
ductase 677C/T subjects (6). Most kits use labeled folic acid
as the competitive binder, and some kit developers have tried to
adjust the assay conditions (eg, pH) to try to equalize the affinity
of folic acid and 5-methyl-THF. However, in general, the serum
and red blood cell folate concentrations measured by these kits
are significantly lower than the concentrations obtained from
microbiological assays (31, 32), which possibly reflects the
higher affinity of the folic acid standard. For this reason, man-
ufacturers sometimes ask individual clinical laboratories to set
their own concentrations from their experience for inadequate
folate status. One manufacturer decreased the actual concen-
tration of its folic acid standard by 30% from the concentration
on the label so that the results with its kit agreed with the results
from microbiological assays.
Generally, the range of folate concentration that laboratories
can measure with these assays is 2–20 ng/mL. Although this
range covers the lower expected serum folate concentrations, in
an age of folate fortification many serum samples contain much
higher concentrations than 20 ng/mL. Assays sometimes require
diluted serum samples, and all red cell assays require consid-
erable dilution because of their much higher folate concen-
trations. Unlike with microbiological assays, matrix effects are
very marked with these binding protein kits and they produce
significant differences in values, which depends on whether
laboratories dilute samples (and standards) with buffer, human
serum albumin, or “folate-free” serum or plasma (30, 32). Pre-
sumably, the matrix (pH, ionic strength, and so forth) influences
the affinity of folates for the binder.
Over the past few years, the major kits that laboratories have
used have been the Bio-Rad (Hercules, CA) Quantaphase II
radioimmunoassay and the Abbott (Abbott Park, IL) AxSYM
Folate ion capture radioimmunoassay. A number of NHANES
cycles (33) have used the Bio-Rad kit. However, the manufacturer
no longer produces this kit, which makes comparisons of earlier
NHANES data with data from future NHANES cycles prob-
lematic. This issue shows a potential concern that can arise with
the use of propriety methods.
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Comparison of the lower values for serum and red cell folate
that laboratories obtain with these binding assay kits with the
values with the L. casei assay also makes interpretation of folate
status and adequacy of populations problematic because L. casei
assays form the basis for current guidelines. Comparisons of kits
from different manufacturers have also indicated wide variations
between kits in the concentrations of serum and red blood cell
folate that they identify (32).
FUNCTIONAL INDICATORS OF FOLATE STATUS
Researchers have used a number of functional indicators of
folate status over the years, which include plasma or urinary
formiminoglutamate, aminoimidazole carboxamide riboside, and
plasma homocysteine; elevations of these indicators reflect im-
paired one-carbon metabolism (1–3). Of these indicators, only
homocysteine has received much traction. Although the levels of
these indicators can change quite dramatically at the very lowest
end of the folate status spectrum, they have little value in the
definition of differences in the folate status of individuals in the
low-normal to normal or even high folate status range because of
a lack of sensitivity in this range. None of these indicators is
specific for folate status because they can be elevated in vitamin
B-12 deficiency and, in the case of homocysteine, vitamin B-6
and riboflavin deficiency (34).
NEWER METHODOLOGIES
Mass spectrometry methods for the assay of folate derivatives
have been reviewed by Pfeiffer et al (32, 35). These methods,
which are still in the developmental stage, have the potential
advantage of allowing the measurement of individual folate spe-
cies, such as themajor derivatives, in serum and red cells, as well as
of relatively minor species, such as unmetabolized folic acid.
This advantage is likely to become even more important in the
future as more information on genetic polymorphisms that affect
nutritional status and folate distributions becomes available.
Because of fortification of the food supply with folic acid, con-
cerns about folate status have shifted from the detection of folate
deficiency in populations toward possible adverse effects of high
folate intake. Mass spectrometry methods potentially allow the
monitoring of the effects of high folic acid intake, such as the
concentrations of folic acid in blood.
Experiencewith previousmethodologies informs us about where
some of the methodologic problems are likely to lie. Although
theoretically every individual folate derivative would be acces-
sible, so many potential derivatives exist that the capture of every
one would be difficult, and a total folate measure would require
the summation of all derivatives. Summation of the parts, as dif-
ferential microbiological assays have shown, introduces additional
error. With red blood cell folate, it may be necessary to hydrolyze
polyglutamates to themonoglutamates to simplify themixture, and
incomplete hydrolysis would decrease recoveries.
Chemical work-up and any derivatization procedures will
probably lead to loss of some species and interconversion of others.
Laboratories can account for losses by the addition of internal
standards for the folate derivatives of interest. However, adjust-
ment for the extent of interconversion of folate forms is more
difficult. Interconversion of species can lead to loss of some forms
and increases in others. For example, if folic acid is of interest, it
will be necessary to ensure that other folate derivatives do not
generate folic acid in situ during the procedure.
BagleyandSelhub(36)havedescribedanintriguingmethodthat
involves purification of folates by binding and elution from an
immobilized folate bindingprotein columnandHPLCseparation of
the individual folate forms in combination with electrochemical
detection. The use of various voltages for the detector allowed the
detection and measurement of individual classes of one-carbon
forms of folate without complete separation of all forms. Studies
have not yet validated this method extensively, particularly with
regard to the stability of individual folate forms and the extent
of their interconversion during the purification and separation
procedures.
CONCLUDING REMARKS
Despite its age, the L. casei microbiological assay procedure
for the measurement of total folate in blood samples remains the
simplest and most easily interpretable method for assessment of
overall folate status in large population survey groups such as
NHANES. Cutoff values for folate status sufficiency are well
established and time trends are easily discerned. Comparisons
with data obtained with other population groups, both large and
small, are straightforward. The mass spectrometry methods for
folate assay, which are currently under development, show much
promise. These methods will need further validation and stan-
dardization to ensure that consistent data are obtained, which
can form the basis for the establishment of new ranges for folate
status sufficiency.
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